CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Age range
3 Years – 75 Years
Last updated December 2024